Literature DB >> 25448629

Concerted modulation of paxillin dynamics at focal adhesions by Deleted in Liver Cancer-1 and focal adhesion kinase during early cell spreading.

Shelly Kaushik1, Archna Ravi, Feroz M Hameed, Boon Chuan Low.   

Abstract

Deleted in Liver Cancer-1 (DLC1) is a RhoGTPase-activating protein (GAP) and a tumor suppressor often downregulated in cancers. It is localized to the focal adhesions (FAs) and its absence leads to enhanced cell migration, invasion, and metastasis. Although DLC1 interacts with focal adhesion kinase (FAK), talin, and tensin, its role in focal adhesions dynamics remains unclear. We examined the effect of DLC1 in Human Foreskin Fibroblasts and determined its localization, dynamics and impact on paxillin by Fluorescence Recovery After Photobleaching at both nascent and mature focal adhesions. During early cell spreading, DLC1 is preferentially localized at the inner/mature adhesions whereas phosphorylated paxillin occupies the outer/nascent FAs. In addition, DLC1 downregulates paxillin turnover in a process, that does not require its GAP activity. Instead, it requires the presence of FAK. Acting in concert, both DLC1 and FAK could provide a unique spatio-temporal mechanism to regulate paxillin function in tissue homeostasis.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  GTPase activating protein (GAP); RhoGTPases; cell dynamics; tumor suppressor

Mesh:

Substances:

Year:  2015        PMID: 25448629     DOI: 10.1002/cm.21201

Source DB:  PubMed          Journal:  Cytoskeleton (Hoboken)        ISSN: 1949-3592


  8 in total

1.  Down-regulation of DLC1 in endothelial cells compromises the angiogenesis process.

Authors:  Yi-Ping Shih; Sarah Y Yuan; Su Hao Lo
Journal:  Cancer Lett       Date:  2017-04-10       Impact factor: 8.679

2.  Epidermal growth factor activates the Rho GTPase-activating protein (GAP) Deleted in Liver Cancer 1 via focal adhesion kinase and protein phosphatase 2A.

Authors:  Archna Ravi; Shelly Kaushik; Aarthi Ravichandran; Catherine Qiurong Pan; Boon Chuan Low
Journal:  J Biol Chem       Date:  2014-12-18       Impact factor: 5.157

3.  DLC1: a tumor suppressor that regulates Rho signaling.

Authors:  Brajendra K Tripathi; Douglas R Lowy
Journal:  Oncotarget       Date:  2017-04-25

Review 4.  Paxillin: a crossroad in pathological cell migration.

Authors:  Ana María López-Colomé; Irene Lee-Rivera; Regina Benavides-Hidalgo; Edith López
Journal:  J Hematol Oncol       Date:  2017-02-18       Impact factor: 17.388

5.  Mechanotransduction in talin through the interaction of the R8 domain with DLC1.

Authors:  Alexander William M Haining; Rolle Rahikainen; Ernesto Cortes; Dariusz Lachowski; Alistair Rice; Magdalena von Essen; Vesa P Hytönen; Armando Del Río Hernández
Journal:  PLoS Biol       Date:  2018-07-20       Impact factor: 8.029

6.  Pan-cancer analysis reveals an immunological role and prognostic potential of PXN in human cancer.

Authors:  Yun Chen; Han Zhao; Yan Xiao; Peijun Shen; Li Tan; Shaohui Zhang; Qiong Liu; Zhengrong Gao; Jie Zhao; Yaqiong Zhao; Yue Guo; Yunzhi Feng
Journal:  Aging (Albany NY)       Date:  2021-06-16       Impact factor: 5.682

7.  An epigenetic signature of adhesion molecules predicts poor prognosis of ovarian cancer patients.

Authors:  Ping-Ying Chang; Yu-Ping Liao; Hui-Chen Wang; Yu-Chih Chen; Rui-Lan Huang; Yu-Chi Wang; Chiou-Chung Yuan; Hung-Cheng Lai
Journal:  Oncotarget       Date:  2017-06-16

8.  Proteasomal turnover of the RhoGAP tumor suppressor DLC1 is regulated by HECTD1 and USP7.

Authors:  Yannick Frey; Mirita Franz-Wachtel; Boris Macek; Monilola A Olayioye
Journal:  Sci Rep       Date:  2022-03-23       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.